Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.
暂无分享,去创建一个
H. Bregman | J. Newcomb | P. Andrews | Xin Huang | Cindy A. Wilson | C. Strathdee | Liyue Huang | Y. Teffera | H. Gunaydin | Yan Gu | Nagasree Chakka | A. Guzman-Perez | V. Berry | Jingzhou Liu | Bryan Egge | E. Mullady | Steve Schneider | Ankita Mishra | R. Serafino | S. Turci | E. Dimauro | R. Emkey | Mary K. Stanton | D. Saffran | J. L. Buchanan | Zihao Hua | Lisa Acquaviva | J. Dovey
[1] D. Chin,et al. Structure-efficiency relationship of [1,2,4]triazol-3-ylamines as novel nicotinamide isosteres that inhibit tankyrases. , 2013, Journal of medicinal chemistry.
[2] D. Chin,et al. Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor. , 2013, Journal of medicinal chemistry.
[3] S. Krauss,et al. Tankyrases as drug targets , 2013, The FEBS journal.
[4] P. Nordlund,et al. Fragment-based ligand design of novel potent inhibitors of tankyrases. , 2013, Journal of medicinal chemistry.
[5] Steve Schneider,et al. Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors. , 2013, Journal of medicinal chemistry.
[6] S. Krauss,et al. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. , 2013, Cancer research.
[7] A. Fallarero,et al. Screening and structural analysis of flavones inhibiting tankyrases. , 2013, Journal of medicinal chemistry.
[8] G. Drewes,et al. Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor. , 2013, Journal of medicinal chemistry.
[9] H. Bregman,et al. Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket. , 2013, Journal of medicinal chemistry.
[10] A. Ashworth,et al. Tankyrase-targeted therapeutics: expanding opportunities in the PARP family , 2012, Nature Reviews Drug Discovery.
[11] April Chen,et al. Use of uptake intrinsic clearance from attached rat hepatocytes to predict hepatic clearance for poorly permeable compounds , 2012, Xenobiotica; the fate of foreign compounds in biological systems.
[12] H. Dinh,et al. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. , 2012, Cancer research.
[13] Xin Huang,et al. Novel Binding Mode of a Potent and Selective Tankyrase Inhibitor , 2012, PloS one.
[14] D. Chin,et al. [1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding. , 2012, Journal of medicinal chemistry.
[15] L. Lehtiö,et al. Structural basis of selective inhibition of human tankyrases. , 2012, Journal of medicinal chemistry.
[16] Natalia Markova,et al. Structural basis for the interaction between tankyrase-2 and a potent Wnt-signaling inhibitor. , 2010, Journal of medicinal chemistry.
[17] D. Ferraris,et al. Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. , 2010, Journal of medicinal chemistry.
[18] Marc W. Kirschner,et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling , 2009, Nature.
[19] L. Lum,et al. Structure-activity relationship studies of small-molecule inhibitors of Wnt response. , 2009, Bioorganic & medicinal chemistry letters.
[20] Lawrence Lum,et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer , 2008, Nature chemical biology.
[21] A. Ashworth,et al. DNA repair deficiency as a therapeutic target in cancer. , 2008, Current opinion in genetics & development.
[22] P. Polakis. The many ways of Wnt in cancer. , 2007, Current opinion in genetics & development.
[23] Hans Clevers,et al. Mining the Wnt pathway for cancer therapeutics , 2006, Nature Reviews Drug Discovery.
[24] Hans Clevers,et al. Wnt/β-Catenin Signaling in Development and Disease , 2006, Cell.
[25] H. Clevers,et al. Wnt signalling in stem cells and cancer , 2005, Nature.
[26] Y. Terelius,et al. Use of a cocktail of probe substrates for drug-metabolizing enzymes for the assessment of the metabolic capacity of hepatocyte preparations , 2004, Xenobiotica; the fate of foreign compounds in biological systems.
[27] T. Lange,et al. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. , 1998, Science.
[28] V. Marquez,et al. Ara-tiazofurin: conservation of structural features in an unusual thiazole nucleoside. , 1988, Journal of medicinal chemistry.
[29] P. Guzelian,et al. PHENOTYPIC STABILITY OF ADULT RAT HEPATOCYTES IN PRIMARY MONOLAYER CULTURE * , 1980, Annals of the New York Academy of Sciences.
[30] H. Dinh,et al. Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth. , 2011, Cancer research.
[31] Philip Jones,et al. Development of Poly(ADP-Ribose)Polymerase (PARP) Inhibitors in Oncology , 2010 .